Analyst values Vyome’s VT-1953 at USD 1 Billion upon successful completion of phase 3 study

New Delhi:  Vyome Holdings, Inc. has announced key findings from an independent U.S. market assessment, commercial forecast, and valuation analysis commissioned by Vyome and conducted by Destum Partners, Inc., a reputed life sciences strategy and transaction advisory firm.

The independent analysis evaluated VT-1953, Vyome’s lead clinical candidate for the treatment of symptoms of malignant fungating wounds (MFW), a rare and devastating complication of advanced solid tumors associated with severe malodor, pain, and profound psychosocial distress.

“Malignant fungating wounds represent one of the most severe and underserved conditions in oncology supportive care,” said Tom Filipczak, Managing Director and Partner at Destum Partners. “Our team conducted rigorous primary and secondary research, including clinician interviews, epidemiology modeling, pricing benchmarking, and valuation analyses. Based on the absence of approved therapies and the high unmet need, we believe this indication represents a compelling clinical and commercial opportunity.”

According to Destum Partners’ comprehensive assessment, the total addressable pharmacologic market in the United States for malignant fungating wounds is estimated to be approximately USD 2.2 billion. Based on a bottom-up commercial model, estimated peak annual net sales for VT-1953 are approximately USD 600 million. Using a risk-adjusted net present value (rNPV) methodology, the estimated U.S. asset value as of now, with the successful and positive Phase 2 data, is projected to be USD 455 million, and following successful Phase 3 completion, is projected to approach USD 1 billion.

“This independent analysis reinforces our conviction in the potential of VT-1953,” said Venkat Nelabhotla, Chief Executive Officer of Vyome. “We engaged a highly experienced third-party consulting firm to conduct a rigorous and unbiased assessment of the commercial opportunity for this program, where there are currently no FDA-approved drugs. Destum Partners’ conclusion around the total addressable market in the U.S., together with the modeled potential peak sales and significant post-Phase 3 potential valuation, provides important external validation as we seek to advance VT-1953 toward pivotal development.”

The analysis by Destum Partners incorporated extensive secondary research, epidemiology modeling, competitive landscape evaluation, pricing benchmarking, and primary research interviews with key opinion leaders across oncology, palliative care, wound care, and hospice settings.